Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18742534 | 0.95 | HDAC3 (0.65) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742411 | 0.95 | HDAC3 (0.65) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16677936 | 0.94 | HDAC6 (0.67) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18712282 | 0.94 | HDAC3 (0.65) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16632207 | 0.92 | HDAC3 (0.55) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16677935 | 0.92 | HDAC3 (0.55) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL17832599 | 0.91 | HDAC1 (0.62) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16644384 | 0.90 | HDAC3 (0.66) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16644382 | 0.89 | HDAC3 (0.70) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16644404 | 0.89 | HDAC3 (0.69) | VNN1HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| EP-4410284-A1 | COMPOUND AND METHOD FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | Apteeus (FR) | 2024-08-07 | — | — | EP | claimed |
| US-20230391868-A1 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | THE GEORGE WASHINGTON UNIVERSITY | 2023-12-07 | — | — | US | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| CN-114908049-A | Use of HDAC6 inhibitors to selectively induce T cell expansion | 江苏集萃医学免疫技术研究所有限公司 | 2022-08-16 | — | — | CN | claimed |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-115192714-B | Use of HDAC6 inhibitors in the manufacture of a medicament for the treatment of DNMT3A gene-deficient cancers | 沈阳药科大学 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024160990-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | APTEEUS (FR) | 2024-08-08 | — | — | WO | disclosed |
| EP-4410284-A1 | COMPOUND AND METHOD FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | Apteeus (FR) | 2024-08-07 | — | — | EP | disclosed |
| US-20150176076-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150150871-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150105358-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105383-A1 | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054197-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NON-HODGKIN'S LYMPHOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105409-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA | Acetylon Pharmaceticals, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054175-A1 | COMBINATIONS OF HISTONE DEACTYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105409-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA | BTK, HDAC2, HDAC5 | VNN1 1989/4885HDAC3 10/4885HDAC1 8/4885 |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | VNN1 1112/4885HDAC3 7/4885HDAC1 2/4885 |
| US-20150150871-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | HDAC5, HDAC4, HDAC3 | VNN1 1405/4885HDAC3 3/4885HDAC1 5/4885 |
| US-20230391868-A1 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | CD47, HDAC6, HDAC3 | VNN1 3761/4885HDAC3 3/4885HDAC1 4/4885 |
| US-20150105383-A1 | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma | HDAC5, HDAC9, HDAC4 | VNN1 1346/4885HDAC3 8/4885HDAC1 5/4885 |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | HDAC6, HDAC2, HDAC5 | VNN1 1446/4885HDAC3 7/4885HDAC1 6/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | VNN1 2427/4885HDAC3 2/4885HDAC1 3/4885 |
| US-20150176076-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | HDAC5, HDAC6, HDAC9 | VNN1 2171/4885HDAC3 8/4885HDAC1 7/4885 |
| US-20150105358-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | HDAC5, HDAC4, HDAC2 | VNN1 1312/4885HDAC3 6/4885HDAC1 5/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | VNN1 1112/4885HDAC3 7/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.